PDA Releases Technical Report on TBA and TCA Odors and Taints
PDA Releases Technical Report on TBA and TCA Odors and Taints
The Parenteral Drug Association has released guidance on the detection and mitigation of 2,4,6-Tribromoanisole (TBA) and 2,4,6-Trichloroanisole (TCA) taints and odors in pharmaceutical and healthcare products.
Technical Report Number 55 (TR 55) provides information on the origin of TBA and TCA odors and taints, analytical methods developed, and risk management strategies. The report highlights the uses of 2,4,6-tribromophenol (TBP) and 2,4,6-trichlorophenol (TCP); the role of fungal halophenol methylation that generates TBA and TCA haloanisole taints; and sensory and physiochemical properties of TBP, TCP, TBA, and TCA. The report also gives case examples of recalls, the root causes behind those recalls, and remedial actions taken.
From 2009 to 2011, companies in the pharmaceutical and consumer healthcare industries experienced product recalls due to the risk of product exposure to the TBA taint from tribromophenol-treated wood pallets. TR 55 offers “guidance on signal detection from adverse event and/or product quality complaints and resulting recalls, toxicology and safety, analytical method development and use, supply chain controls, risk analysis and mitigation.”
PDA members can access TR 55 for free until May 31, 2012.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
